跳至主要内容
临床试验/EUCTR2018-004072-35-FR
EUCTR2018-004072-35-FR进行中(未招募)1 期

Study of the value of early treatment with an endothelin inhibitor (Bosentan) in patients with sudden blindness secondary to giant cell arteritis - CECIBO

CHU de Nice0 个研究点目标入组 8 人开始时间: 2018年11月6日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
CHU de Nice
入组人数
8

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Age > 50 years old
  • Decreased visual acuity (BVA), regardless of degree of severity, sudden onset in the context of newly diagnosed or suspected Horton's disease
  • Diagnostic BAV <58 days
  • Conventional treatment of Horton's disease: Corticosteroids and + - anti-platelet aggregators and / or LMWH at the discretion of the referring physician for his vascularity and + - immunosuppressive or biologic pathology if necessary.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 4
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 4

排除标准

  • BAV and ischemia over 5 days
  • Underlying hepatocellular insufficiency known
  • Patient under guardianship or curatorship
  • Hypersensitivity to the active substance or to any of the excipients
  • Moderate to severe hepatic insufficiency corresponding to class B or C of the Child-Pugh classification
  • Serum levels of hepatic aminotransferases, aspartate aminotransferases (ASTs) and / or alanine aminotransferases (ALATs), greater than 3 times the upper limit of normal before start of treatment
  • Patient on cyclosporine A therapy

研究者

发起方
CHU de Nice

相似试验